Company intelligence / Profile preview

beBit

Cambridge, Massachusetts, United Statesbebit.it ↗

Ownership: Private
Development stage: Other

Overview

Be Biopharma has initiated a Phase 1/2 trial ("BeCoMe‑9") for its lead candidate BE‑101 in hemophilia B after receiving IND clearance and FDA Fast Track designation. Preclinical data for its second candidate, BE‑102 for hypophosphatasia, have been announced. The company’s BCM platform enables durable, titratable expression of therapeutic proteins via engineered human B cells without preconditioning. Both programs aim to address high unmet needs with potentially best-in-class genetic medicines.

Therapeutic areas: Rare DiseasesHematology
Modalities: Cell therapyGene therapyEngineered B cell medicine
Industry: Biotech

Partnerships

Bristol Myers SquibbTakeda VenturesSeattle Children’s Research InstitutePathway to Cures/National Bleeding Disorders Foundation

Beyond the preview

Go deeper on beBit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on beBit.

Explore the full profile